top of page
The Future of Metabolic Health:  Regenerative, Not Just Reactive
Three Pathways to Market

We are leveraging the unique mechanism of action of CREO through a tiered approach. This allows MBH to maximizing our intellectual property while addressing different market segments from wellness to intensive clinical therapy.

1. The Natural Health Solution (Fastest to Market)

  • The Product: A synergistic Probiotic + Herb combination.

  • How it works: We provide a specific probiotic strain paired with a targeted herbal substrate that the bacteria "eat" to naturally produce 4-cresol directly in the gut.

  • The Advantage: A lower regulatory barrier and a faster path to revenue, offering consumers a scientifically backed way to support glucose health and weight management naturally.

2. The Bio-Engineered Approach (The eLBP)

  • The Product: An Engineered Live Biotherapeutic Product (eLBP).

  • How it works: Using advanced synthetic biology, we are engineering a "friendly" microbe designed to be a 4-Cresol factory, overproducing the metabolite within the microbiome.

  • The Advantage: This sits at the cutting edge of microbiome science, providing a potent, precise, self-sustaining biological therapy for chronic metabolic conditions.

3. The Pharmaceutical Pipeline (High-Value Therapy)

  • The Product: 4-Cresol as a standardized, precision drug.

  • How it works: A direct, pharmaceutical-grade delivery of the 4-cresol molecule.

  • The Advantage: This follows the traditional FDA/EMA clinical pathway to treat acute diseases like Type 2 Diabetes and NASH. It offers a high level of potency and "disease-modifying" potential, representing a massive opportunity for investors.

Strategic Advantage:

Revenue Diversification: Short-term gains from nutraceuticals fund long-term pharmaceutical R&D.

Market Coverage: We can reach the "pre-diabetic" consumer and the "chronic patient" simultaneously.

Synergistic R&D: Core scientific work on the 4-Cresol molecule, such as understanding its pharmacokinetics (PK) and safety profile, directly informs and de-risks all three pipelines (Natural Health, eLBP, and Pharmaceutical), creating a complementary program.

IP Protection: Our deep understanding of the 4-Cresol pathway allows us to build a "moat" around the entire metabolite ecosystem.

​​

​

bottom of page